Renal Business Today

Aranesp

Should ESA Label Change Affect QIP Program?

On June 24, Amgen announced an FDA-approved label change to its anemia drugs Epogen and Aranesp, but could the change conflict with the Quality Improvement Plan (QIP) that is connected to the bundle? ...More
June 27, 2011
Posted in Blog, Government & Regulation
Amgen Updates Labeling for Epogen, Aranesp

THOUSAND OAKS, Calif.—Amgen has modified the labeling of its erythropoiesis-stimulating agents (ESAs)—Aranesp and Epogen—to include information about the increased risk of cardiovascular reactions and updated prescribing information in patients with chronic kidney disease ...More
June 24, 2011
Posted in News, Clinical & Pharma, Government & Regulation
AAKP Response to MEDCAC's ESA Decision

TAMPA, Fla.—The American Association of Kidney Patients (AAKP) submitted on Jan. 31 a letter to the Centers for Medicare & Medicaid Services (CMS) on its concerns regarding the outcome of the recent Medicare Evidence Development & Coverage Advisory Committee ...More
February 9, 2011
Posted in News, Government & Regulation
Poor Anemia Drug Response Predicts Heart Disease, Death

DALLAS—Patients with diabetes, kidney disease and anemia who don't respond to treatment with an anti-anemia drug have a higher risk of cardiovascular disease or death, according to researchers at UT Southwestern Medical Center. ...More
December 29, 2010
Posted in News, Clinical & Pharma
Use of Anemia Drugs in CKD Stabilizing

EXTON, Pa.— The use of erythropoietin-stimulating agents (ESAs) in patients with chronic kidney disease not on dialysis (CKD-ND) is showing signs of stabilization, according to the latest survey released by BioTrends Research. ...More
October 27, 2010
Posted in News, Clinical & Pharma, Practice Management
FDA Panel Votes to Continue Use of Anemia Drugs for CKD

A U.S. Food and Drug Administration (FDA) panel voted 15-1 in favor of maintaining approval for erythropoietin-stimulating agents (ESAs) to treat anemia in chronic kidney disease patients, according to a report from NPR. ...More
October 18, 2010
Posted in Blog, Government & Regulation
FDA Considers Limiting Anemia Drug Use for Kidney Disease

Because widely used anemia drugs may double the risk of stroke in patients with kidney disease, the Food and Drug Administration is considering new restrictions on them. On Thursday, the FDA posted a safety review of three medications from Amgen Inc., Epogen, Procrit, and ...More
October 14, 2010
Posted in News, Clinical & Pharma
CMS to Reconsider Coverage of Anemia Drugs

The U.S. Centers for Medicare and Medicaid Services (CMS) announced yesterday that it is reviewing its coverage of anemia drugs Epogen and Aranesp used to treat patients with kidney disease. ...More
June 17, 2010
Posted in News, Business, Clinical & Pharma, Government & Regulation, Practice Management
Merck Ends Work on Anemia Drug

WHITEHOUSE STATION, N.J—Merck told analysts May 11 that is ended development of a follow-on biologic that would have competed with Amgen’s Aranesp to treat anemia, according to a report in the May 11 Wall Street Journal. ...More
May 12, 2010
Posted in News, Business, Clinical & Pharma
Anemia Study Changed Way Docs Prescribe ESAs

EXTON, Pa.—Recent clinical reports on erythropoietin-stimulating agents have changed the way nephrologists are prescribing anemia drugs, according to recent survey results from BioTrends Research ...More
April 27, 2010
Posted in News, Business, Clinical & Pharma, Practice Management